Piper Sandler Reaffirms its Overweight Rating and $115 Price Target on Boston Scientific Corporation (BSX)

Core Viewpoint - Boston Scientific Corporation (NYSE:BSX) is identified as one of the stocks expected to double in value over the next five years, driven by strong performance and growth potential in its medical device offerings [1][3]. Group 1: Company Performance - Boston Scientific has shown a remarkable 21.4% increase in sales over the past 12 months, indicating strong execution despite recent investor concerns regarding cardiology performance in Q3 [3]. - The company is valued at $145.3 billion and operates in the medical products sector, focusing on the development, manufacturing, and distribution of medical devices across various interventional specialties [2][3]. Group 2: Growth Drivers - The CHAMPION-AF study is highlighted as a significant growth driver for Boston Scientific's Watchman device, positioning it as a potential first-line alternative to medication therapy, which could lead to an annual revenue increase of 250 basis points later in the decade [2]. - Piper Sandler has reaffirmed an Overweight rating and a price target of $115 for Boston Scientific, reflecting confidence in the company's growth prospects [2].